Sumitomo Mitsui DS Asset Management Company Ltd Boosts Position in Kenvue Inc. $KVUE

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Kenvue Inc. (NYSE:KVUE) by 27.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 310,686 shares of the company’s stock after buying an additional 66,192 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Kenvue were worth $5,042,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Integrity Alliance LLC. bought a new stake in Kenvue during the 1st quarter worth approximately $218,000. Geneos Wealth Management Inc. boosted its holdings in Kenvue by 384.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 6,632 shares of the company’s stock valued at $159,000 after purchasing an additional 5,262 shares during the period. Modern Wealth Management LLC grew its position in shares of Kenvue by 27.8% during the 1st quarter. Modern Wealth Management LLC now owns 13,669 shares of the company’s stock valued at $328,000 after purchasing an additional 2,975 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Kenvue by 12.6% in the second quarter. Parallel Advisors LLC now owns 34,038 shares of the company’s stock worth $712,000 after purchasing an additional 3,801 shares during the period. Finally, Bard Financial Services Inc. raised its position in shares of Kenvue by 4.5% in the second quarter. Bard Financial Services Inc. now owns 132,020 shares of the company’s stock worth $2,763,000 after buying an additional 5,730 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the transaction, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.17% of the stock is currently owned by insiders.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $16.82 on Monday. The stock’s 50-day moving average is $16.90 and its 200 day moving average is $18.38. The stock has a market cap of $32.22 billion, a price-to-earnings ratio of 22.42 and a beta of 0.60. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the prior year, the firm earned $0.28 earnings per share. Kenvue’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Analysts Set New Price Targets

Several research firms recently commented on KVUE. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Barclays boosted their price objective on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Citigroup decreased their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.